Insulet (Nasdaq:PODD) announced data supporting the use of its Omnipod 5 automated insulin delivery system in young children. Acton, Massachusetts–based Insulet’s Omnipod 5 significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years old with type 1 diabetes over 12 months of use, according to the company. Earlier this year, the […]
Drug Pumps
Real-world data backs Medtronic’s next-gen MiniMed 780G insulin pump
Medtronic (NYSE:MDT) announced positive real-world data supporting its next-generation MiniMed 780G insulin pump system. Results from real-world analyses in Europe and Chile, along with clinical data, were presented by Medtronic at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans. According to a news release, the MiniMed 780G advanced hybrid closed loop system, designed with […]
Diabeloop, SOOIL partner on automated insulin delivery technology
Diabeloop announced today that it entered into global development and commercial agreements with insulin delivery technology developer SOOIL. Paris-based Diabeloop, which develops therapeutic artificial intelligence (AI) applied to insulin delivery, and SOOIL will pursue and expand upon technical integration between their platforms, building on cooperation that was initiated in February 2020. Get the full story at […]
Insulet breaks ground on $200M manufacturing facility in Malaysia
Insulet (Nasdaq:PODD) announced the groundbreaking of its new Omnipod manufacturing facility in Malaysia. Acton, Massachusetts–based Insulet’s Johor Bahru, Malaysia-based manufacturing facility will produce its Omnipod automated insulin delivery system and strengthen the company’s global manufacturing capabilities. Get the full story at our sister site, Drug Delivery Business News.
Beta Bionics looks to reduce ‘cognitive burden’ for those with diabetes with bionic pancreas
Beta Bionics’ iLet bionic pancreas offers insulin therapy without some of the hurdles associated with treating diabetes. Users of insulin pumps may be used to a certain regimen associated with managing their diabetes. That can include carbohydrate counting, setting basal rates and more. Beta Bionics has set out to change that. With the Concord, Massachusetts-based company’s […]
BD, government warn on cybersecurity issues with BD’s Pyxis, Synapsys systems
The U.S. Cybersecurity & Infrastructure Security Agency (CISA) today released advisories on two products from BD (NYSE:BDX). Vulnerabilities with the BD Pyxis automated medication dispensing system and the BD Synapsys microbiology informatics software were voluntarily reported by Franklin Lakes, New Jersey–based BD through the CISA coordinated vulnerability disclosure program. The BD Pyxis’ vulnerability is labeled […]
Dexcom quashes talk of Insulet merger, says discussions are not ongoing
Dexcom (Nasdaq:DXCM) today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD). Last week, reports circulated saying talks over a potential acquisition were ongoing, with an agreement between the two diabetes technology developers on the horizon in the coming weeks. On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 […]
Medtronic ‘hopeful’ on FDA clearance for next-gen diabetes tech in FY 2023
The Medtronic (NYSE:MDT) diabetes business sputtered in the fourth quarter but could be bolstered by a major regulatory nod this year. The Fridley, Minnesota-based company saw revenues for its diabetes arm fall by 7.7% year-over-year in the fourth quarter amid overall misses on both sales and adjusted earnings per share compared to Wall Street’s expectations. […]
Bigfoot Biomedical adds former Insulet VP as chief commercial officer
Bigfoot Biomedical announced today that it appointed former Insulet executive Matt Rainville as its chief commercial officer. Rainville’s role includes leading the growth of Milpitas, California–based Bigfoot Biomedical’s fully commercial Bigfoot Unity diabetes management program as the company looks to expand access to its offerings. Bigfoot Unity aims to simplify CGMs and the data they produce […]
Vivera picks up new patent for electronic dose-controlled drug delivery devices
Vivera announced today that it received a third U.S. patent for its Zicoh electronic dose-controlled drug delivery device portfolio. Newport Beach, California-based Vivera’s latest patent from the U.S. Patent and Trademark Office (USPTO) secures Zicoh’s rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules and […]
Report: Dexcom in talks to acquire Insulet
Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD). Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg’s sources preferred to remain anonymous […]